In 2011 was created Foresite Capital, which is appeared as VC. The main department of described VC is located in the San Francisco. The company was established in North America in United States.
The current fund was established by Jim Tananbaum. The overall number of key employees were 11.
The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Foresite Capital, startups are often financed by Venrock, Third Rock Ventures, Paladin Capital Group. The meaningful sponsors for the fund in investment in the same round are Cormorant Asset Management, ARCH Venture Partners, Paladin Capital Group. In the next rounds fund is usually obtained by Paladin Capital Group, Merieux Developpement, EcoR1 Capital.
The higher amount of exits for fund were in 2015. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 7-12 investment rounds annually. The real fund results show that this VC is 9 percentage points more often commits exit comparing to other companies. The usual things for fund are deals in the range of 50 - 100 millions dollars. The typical startup value when the investment from Foresite Capital is more than 1 billion dollars. Opposing the other organizations, this Foresite Capital works on 12 percentage points more the average amount of lead investments.
Among the various public portfolio startups of the fund, we may underline AveXis, Intarcia Therapeutics, Audentes Therapeutics Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Health Care, Genetics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Funds with similar focus
|$50M||04 Aug 2021||United States, San Diego|
|$100M||14 Jul 2021||United States, Palo Alto|
|$276M||29 Jun 2021||United States, San Diego|
|$100M||28 Jun 2021||United States, Philadelphia|
|$250M||17 Jun 2021||United States, Sunnyvale|
|$425M||11 Jun 2021||United States, " United States"}|
|$59M||13 May 2021||United States, South San Francisco|
|$110M||11 May 2021||United States, New York|
|$148M||05 May 2021||United States, Hayward|
– XinThera, a company focused on building a small molecule oncology and immunology pipeline, announced that the company has raised $50M in Series B financing. – New investor Orbimed Advisors, LLC joined existing investors Foresite Capital and TTM Capital, bringing the total financing raised to $80M. – The funds will be used to support the firm’s recruiting efforts and build its product pipeline. – XinThera brings together a founder and investors that previously worked together to incubate, fund and launch ... Read more
– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies. – The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others. – All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund. – Proceeds... Read more
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.